Syneos Health Inc (NASDAQ:SYNH) CEO Alistair Macdonald sold 8,143 shares of Syneos Health stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $53.00, for a total value of $431,579.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Alistair Macdonald also recently made the following trade(s):

  • On Tuesday, February 5th, Alistair Macdonald sold 6,697 shares of Syneos Health stock. The stock was sold at an average price of $53.04, for a total value of $355,208.88.

SYNH stock opened at $53.88 on Friday. Syneos Health Inc has a 1-year low of $31.10 and a 1-year high of $54.19. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.97 and a quick ratio of 0.97. The stock has a market capitalization of $5.46 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 1.48 and a beta of 1.51.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its position in Syneos Health by 5.3% in the 4th quarter. BlackRock Inc. now owns 8,461,264 shares of the company’s stock valued at $332,951,000 after buying an additional 425,338 shares in the last quarter. Vanguard Group Inc. increased its position in Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc. now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after buying an additional 624,991 shares in the last quarter. Vanguard Group Inc increased its position in Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after buying an additional 624,991 shares in the last quarter. Clearbridge Investments LLC increased its position in Syneos Health by 13.3% in the 3rd quarter. Clearbridge Investments LLC now owns 3,230,298 shares of the company’s stock valued at $166,522,000 after buying an additional 379,235 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in Syneos Health by 13.1% in the 4th quarter. Mackenzie Financial Corp now owns 3,202,804 shares of the company’s stock valued at $126,030,000 after buying an additional 370,552 shares in the last quarter.

SYNH has been the topic of several recent research reports. SunTrust Banks cut their target price on Syneos Health to $55.00 and set a “buy” rating on the stock in a report on Wednesday, December 19th. Zacks Investment Research downgraded Syneos Health from a “buy” rating to a “hold” rating in a report on Friday, November 30th. ValuEngine raised Syneos Health from a “hold” rating to a “buy” rating in a report on Saturday, November 10th. Barclays cut their target price on Syneos Health from $51.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, January 3rd. Finally, Robert W. Baird set a $60.00 target price on Syneos Health and gave the stock a “buy” rating in a report on Tuesday, January 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Syneos Health has a consensus rating of “Buy” and a consensus price target of $53.44.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/insider-selling-syneos-health-inc-synh-ceo-sells-8143-shares-of-stock/2822674.html.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

See Also: Fundamental Analysis and Individual Investors

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.